Skip to main content

Dr. Yaohan Lam, M.D.

Dermatology (Dermatology Physician)

  • Medicare participating

At a glance

Years since graduation
16
In the NPI registry since
2010
Medicare patients seen, 2024
854

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2010Medical school: University of Oklahoma College of Medicine
  • 2010Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Dermatology Physician primary
    OK license 27838

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Dermatology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
854
Services billed
3,289
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Destruction of precancer skin growth, 2-14 growths1,130172
Established patient office or other outpatient visit, 20-29 minutes526408
Destruction of precancer skin growth, 1 growth283233
Biopsy of related skin growth, first growth209186
Established patient office or other outpatient visit, 30-39 minutes143109
New patient office or other outpatient visit, 30-44 minutes119119
Established patient office or other outpatient visit, 10-19 minutes9280
Destruction of precancer skin growth, 15 or more growths5848
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm5348
New patient office or other outpatient visit, 15-29 minutes5151

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 16 companies reported 133 payments worth $33,352 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$29,850
Food and Beverage$2,029
Travel and Lodging$1,274
Education$198

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 29, 2025Incyte Corporation
Apr 29, 2025
Compensation for services other than consulting (speaking, faculty)
Opzelura · Dermatology
$7,200
Jul 18, 2025Lilly USA, LLC
Jul 18, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Jun 23, 2025Lilly USA, LLC
Jun 23, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Sep 8, 2025Lilly USA, LLC
Sep 8, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Sep 9, 2025Lilly USA, LLC
Sep 9, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Jul 17, 2025Lilly USA, LLC
Jul 17, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Oct 27, 2025Lilly USA, LLC
Oct 27, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Sep 9, 2025Lilly USA, LLC
Sep 9, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$1,750
Jul 18, 2025Lilly USA, LLC
Jul 18, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$1,750
Aug 15, 2025Lilly USA, LLC
Aug 15, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$1,000
All 28 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Oct 27, 2025Lilly USA, LLC
Oct 27, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Oct 27, 2025Lilly USA, LLC
Oct 27, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$750
Oct 16, 2025Incyte Corporation
Oct 16, 2025
Compensation for services other than consulting (speaking, faculty)
Opzelura · Dermatology
$600
Sep 24, 2025Lilly USA, LLC
Sep 24, 2025
Travel and Lodging
EBGLYSS · Immunology · travel to KANSAS CITY, MO
$30.00
Sep 9, 2025Lilly USA, LLC
Sep 9, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Sep 9, 2025Lilly USA, LLC
Sep 9, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$1,750
Sep 8, 2025Lilly USA, LLC
Sep 8, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Sep 4, 2025Lilly USA, LLC
Sep 4, 2025
Travel and Lodging
travel to KANSAS CITY, MO · in-kind
$182
Aug 20, 2025Janssen Biotech, Inc.
Aug 20, 2025
Education
TREMFYA · Immunology · in-kind
$99.00
Aug 15, 2025Lilly USA, LLC
Aug 15, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$1,000
Jul 23, 2025Lilly USA, LLC
Jul 23, 2025
Travel and Lodging
EBGLYSS · Immunology · travel to SANDESTIN, FL
$30.00
Jul 23, 2025Lilly USA, LLC
Jul 23, 2025
Travel and Lodging
EBGLYSS · Immunology · travel to SANDESTIN, FL
$4.00
Jul 18, 2025Lilly USA, LLC
Jul 18, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Jul 18, 2025Lilly USA, LLC
Jul 18, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$1,750
Jul 17, 2025Lilly USA, LLC
Jul 17, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Jul 15, 2025Lilly USA, LLC
Jul 15, 2025
Travel and Lodging
travel to SANDESTIN, FL · in-kind
$335
Jun 23, 2025Lilly USA, LLC
Jun 23, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$2,000
Jun 12, 2025Lilly USA, LLC
Jun 12, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$1,000
May 22, 2025Lilly USA, LLC
May 22, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$1,000
May 16, 2025Incyte Corporation
May 16, 2025
Compensation for services other than consulting (speaking, faculty)
Opzelura · Dermatology
$300
May 9, 2025Lilly USA, LLC
May 9, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$500
Apr 29, 2025Incyte Corporation
Apr 29, 2025
Compensation for services other than consulting (speaking, faculty)
Opzelura · Dermatology
$7,200
Apr 15, 2025Janssen Biotech, Inc.
Apr 15, 2025
Education
TREMFYA · Immunology · in-kind
$99.00
Apr 5, 2025Incyte Corporation
Apr 5, 2025
Travel and Lodging
Opzelura · Dermatology · travel to Rosemont, IL
$238
Apr 4, 2025Incyte Corporation
Apr 4, 2025
Travel and Lodging
Opzelura · Dermatology · travel to Rosemont, IL
$405
Apr 4, 2025Incyte Corporation
Apr 4, 2025
Travel and Lodging
Opzelura · Dermatology · travel to Oklahoma City, OK
$50.00
Feb 13, 2025Lilly USA, LLC
Feb 13, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$1,000
Jan 29, 2025Lilly USA, LLC
Jan 29, 2025
Compensation for services other than consulting (speaking, faculty)
EBGLYSS · Immunology
$1,000

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Oklahoma →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $357,171 in research payments for these studies, mostly to the institutions running them.

  • A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
    UCB SA · Completed · NCT05277571
  • A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
    Incyte Corporation
  • A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-nave Metastatic Castration-resistant Prostate Cancer
    Amgen Inc.
  • A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Mod…
    Janssen Research & Development, LLC
  • Observation priority e short - lebrikizumab - atopic dermatitis
    Eli Lilly and Company
  • A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream
    Incyte Corporation
  • A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis
    Incyte Corporation
  • A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
    Incyte Corporation
  • A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria
    Incyte Corporation
  • A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK)
    E.r. Squibb & Sons, L.l.c.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in Oklahoma City

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 18, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1285954305. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.